Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major neuropathic pain markets reached a value of US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.
The neuropathic pain market has been comprehensively analyzed in IMARC's new report titled "Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuropathic pain is a type of chronic pain that is caused by damage or dysfunction of the nerves. Some of the common symptoms include burning, shooting, or tingling sensations, numbness, heightened sensitivity to touch, etc. The pain can be constant or intermittent and may be felt in a specific area or spread throughout the body. Additionally, individuals with neuropathic pain may experience weakness or loss of sensation in the affected areas. The diagnosis typically involves a combination of medical history, physical examination, and tests to determine the presence of neuropathic pain. During a physical exam, the healthcare provider may look for signs of nerve damage, such as weakness, loss of sensation, or reflex changes, and may perform some tests to assess the function of the affected nerves. Several diagnostic tests, including nerve conduction studies or imaging tests, are done to confirm the presence of nerve damage and identify the specific cause of the pain.
The increasing prevalence of chronic diseases that cause nerve damage and the rising incidences of peripheral nerve injuries are primarily driving the global neuropathic pain market. In addition to this, the inflating usage of anticonvulsants and tricyclic antidepressants for stabilizing nerve cells and reducing the release of certain neurotransmitters is further propelling the market growth. Moreover, the widespread adoption of nerve blocks, such as epidural injections, for blocking the transmission of pain signals to the brain is also creating a positive outlook for the market. Apart from this, the emerging popularity of transcutaneous electrical nerve stimulation (TENS), a non-invasive pain management therapy that uses low-voltage electrical currents to stimulate nerve fibers and relieve pain, is also bolstering the market growth. Furthermore, the increasing utilization of psychological treatments, including cognitive-behavioral therapy and mindfulness-based interventions, for managing the emotional and psychological aspects of neuropathic pain is acting as another significant growth-inducing factor. Additionally, the rising adoption of nerve stimulation techniques, such as spinal cord stimulation, peripheral nerve stimulation, deep brain stimulation, etc., to alleviate symptoms by stimulating specific nerves or areas of the brain associated with the pain is expected to drive the global neuropathic pain market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the neuropathic pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuropathic pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuropathic pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuropathic pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuropathic pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuropathic pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neuropathic pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuropathic pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuropathic pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neuropathic pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuropathic pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuropathic pain by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuropathic pain by type across the seven major markets?
How many patients are diagnosed (2018-2034) with neuropathic pain across the seven major markets?
What is the size of the neuropathic pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuropathic pain?
What will be the growth rate of patients across the seven major markets?
Neuropathic Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuropathic pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuropathic pain market?
What are the key regulatory events related to the neuropathic pain market?
What is the structure of clinical trial landscape by status related to the neuropathic pain market?
What is the structure of clinical trial landscape by phase related to the neuropathic pain market?
What is the structure of clinical trial landscape by route of administration related to the neuropathic pain market?
The neuropathic pain market has been comprehensively analyzed in IMARC's new report titled "Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuropathic pain is a type of chronic pain that is caused by damage or dysfunction of the nerves. Some of the common symptoms include burning, shooting, or tingling sensations, numbness, heightened sensitivity to touch, etc. The pain can be constant or intermittent and may be felt in a specific area or spread throughout the body. Additionally, individuals with neuropathic pain may experience weakness or loss of sensation in the affected areas. The diagnosis typically involves a combination of medical history, physical examination, and tests to determine the presence of neuropathic pain. During a physical exam, the healthcare provider may look for signs of nerve damage, such as weakness, loss of sensation, or reflex changes, and may perform some tests to assess the function of the affected nerves. Several diagnostic tests, including nerve conduction studies or imaging tests, are done to confirm the presence of nerve damage and identify the specific cause of the pain.
The increasing prevalence of chronic diseases that cause nerve damage and the rising incidences of peripheral nerve injuries are primarily driving the global neuropathic pain market. In addition to this, the inflating usage of anticonvulsants and tricyclic antidepressants for stabilizing nerve cells and reducing the release of certain neurotransmitters is further propelling the market growth. Moreover, the widespread adoption of nerve blocks, such as epidural injections, for blocking the transmission of pain signals to the brain is also creating a positive outlook for the market. Apart from this, the emerging popularity of transcutaneous electrical nerve stimulation (TENS), a non-invasive pain management therapy that uses low-voltage electrical currents to stimulate nerve fibers and relieve pain, is also bolstering the market growth. Furthermore, the increasing utilization of psychological treatments, including cognitive-behavioral therapy and mindfulness-based interventions, for managing the emotional and psychological aspects of neuropathic pain is acting as another significant growth-inducing factor. Additionally, the rising adoption of nerve stimulation techniques, such as spinal cord stimulation, peripheral nerve stimulation, deep brain stimulation, etc., to alleviate symptoms by stimulating specific nerves or areas of the brain associated with the pain is expected to drive the global neuropathic pain market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the neuropathic pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuropathic pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuropathic pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuropathic pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuropathic pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuropathic pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neuropathic pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuropathic pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuropathic pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neuropathic pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuropathic pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuropathic pain by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of neuropathic pain by type across the seven major markets?
How many patients are diagnosed (2018-2034) with neuropathic pain across the seven major markets?
What is the size of the neuropathic pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuropathic pain?
What will be the growth rate of patients across the seven major markets?
Neuropathic Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuropathic pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuropathic pain market?
What are the key regulatory events related to the neuropathic pain market?
What is the structure of clinical trial landscape by status related to the neuropathic pain market?
What is the structure of clinical trial landscape by phase related to the neuropathic pain market?
What is the structure of clinical trial landscape by route of administration related to the neuropathic pain market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROPATHIC PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROPATHIC PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROPATHIC PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NEUROPATHIC PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROPATHIC PAIN - UNMET NEEDS
10 NEUROPATHIC PAIN - KEY ENDPOINTS OF TREATMENT
11 NEUROPATHIC PAIN - MARKETED PRODUCTS
11.1 List of Neuropathic Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Lyrica (Pregabalin) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nucynta ER (Tapentadol controlled-release) - Grunenthal/Janssen /Ortho-McNeil
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Cymbalta (Duloxetine) - Eli Lilly and Company
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Qutenza (Capsaicin dermal patch) - Grunenthal
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NEUROPATHIC PAIN - PIPELINE DRUGS
12.1 List of Neuropathic Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 AP 325 - Algiax Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ACD440 - AlzeCure Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ralfinamide - Newron Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Halneuron - WEX Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LAT 8881 - Lateral Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROPATHIC PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROPATHIC PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROPATHIC PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neuropathic Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neuropathic Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neuropathic Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neuropathic Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neuropathic Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neuropathic Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neuropathic Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neuropathic Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neuropathic Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neuropathic Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neuropathic Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neuropathic Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neuropathic Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neuropathic Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neuropathic Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neuropathic Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neuropathic Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neuropathic Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neuropathic Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neuropathic Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neuropathic Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neuropathic Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neuropathic Pain - Access and Reimbursement Overview
16 NEUROPATHIC PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROPATHIC PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROPATHIC PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROPATHIC PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROPATHIC PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROPATHIC PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NEUROPATHIC PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROPATHIC PAIN - UNMET NEEDS
10 NEUROPATHIC PAIN - KEY ENDPOINTS OF TREATMENT
11 NEUROPATHIC PAIN - MARKETED PRODUCTS
11.1 List of Neuropathic Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Lyrica (Pregabalin) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nucynta ER (Tapentadol controlled-release) - Grunenthal/Janssen /Ortho-McNeil
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Cymbalta (Duloxetine) - Eli Lilly and Company
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Qutenza (Capsaicin dermal patch) - Grunenthal
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NEUROPATHIC PAIN - PIPELINE DRUGS
12.1 List of Neuropathic Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 AP 325 - Algiax Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ACD440 - AlzeCure Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ralfinamide - Newron Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Halneuron - WEX Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LAT 8881 - Lateral Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NEUROPATHIC PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NEUROPATHIC PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROPATHIC PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neuropathic Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neuropathic Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neuropathic Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neuropathic Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neuropathic Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neuropathic Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neuropathic Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neuropathic Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neuropathic Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neuropathic Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neuropathic Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neuropathic Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neuropathic Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neuropathic Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neuropathic Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neuropathic Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neuropathic Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neuropathic Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neuropathic Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neuropathic Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neuropathic Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neuropathic Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neuropathic Pain - Access and Reimbursement Overview
16 NEUROPATHIC PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROPATHIC PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROPATHIC PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
